Recombinant Biotinylated Human OX40, Fc Tag, Avi Tag (Avitag™), 25µg

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Biotinylated Human OX40, Fc,Avitag (OX0-H82F7) is expressed from human 293 cells (HEK293). It contains AA Leu 29 - Ala 216 (Accession # NP_003318).
Predicted N-terminus: Leu 29

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™). The protein has a calculated MW of 48.6 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors"
Goldman, Piha-Paul, Curti et al
Clin Cancer Res (2022)
(2) "First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors"
Kim, Burris, de Miguel Luken et al
Clin Cancer Res (2022)
(3) "High soluble OX40 levels correlate with metastatic gastric cancer"
Lima, Martins, Dos Santos et al
J Surg Oncol (2022) 126 (1), 139-143
Showing 1-3 of 1816 papers.